United Kingdom (UK)
Recombinant monoclonal antibody to antibody 14G2a. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma 1A7.
Alternative Name(s) of Target: idiotype of 14G2a; 14G2a; anti-ID; GD2; ganglioside GD2; disialoganglioside GD2
Immunogen: The anti-idiotypic antibody 1A7 was raised by immunizing BALB/c mice with a mouse anti-GD2 antibody 14G2a.
Specificity: 1A7 is specific for an idiotype of the anti-ganglioside GD2 antibody 14G2a and behaves as an internal image of GD2.
Application Notes: Various cancers, such as melanoma, neuroblastoma, glioma, soft tissue sarcoma, and small cell carcinoma involve overexpression of ganglioside GD2. Traditional therapeutic approaches comprised of attempts to administer anti-GD2 antibodies to deplete the cencer cells. However, such intervetions often lead to the development of the immune response against those therapeutic antibides or the cytotoxic activation against the tumor cells casued by the therapuetic was insufficient. The solution to this problem might be the generation of an anti-idiotypic antibody (Ab2) against a primary antibody which can bind GD2 (Ab1). Such an anti-idiotypic antibody (Ab2) works as an internal image of the antigen (GD2) and, upon administration to a subject with a Gd2-positive tumor, can lead to the generation of anti-anti-idiotypic antibodies (Ab3) which will be directed against GD2 and will lead to the depletion of the tumor. 1A7 is such an anti-idiotypic antibody (Ab2) which was demonstrated to functionally mimic the tumor - associated antigen disialoganglioside GD2 (Sen et al., 1997; pmid: 9815586). 1A7 was shown to be able to induce the production of the anti-anti-idiotypic antibodies (Ab3) directed against GD2 in mice, rabbits and nonhuman primates (Sen et al., 1997; pmid: 9815586). It was capable of reacting with the GD2-positive melanoma cell line M21/P6 cells but not with GD2-negative LS174-T cells (Sen et al., 1997; pmid: 9815586). Finally, in a phase I clinical trial immunization of patients with 1A7, mixed with the adjuvant QS21, demonstrated that 1A7 could act as a surrogate antigen for GD2 and induce strong humoral immune responses in advanced stage melanoma patients (Zeytin et al., 2000; pmid: 11129285). Consequently; this clone can be further recommended for the development of effective approaches targeting GD2-positive cancers. 1A7 was used for flow cytometry (FC) to detect chimeric antigen receptor (CAR) expression by transduced T lymphocytes (Yvon et al., 2009; PMID: 19737958). Dylight 650- or 488-conjugated 1A7 was used to measure T-cell transduction in flow cytometry analysis. 1A7 was also used as a proliferation stimulus in MDSC (myeloid-derived suppressor cell) suppression assays to evaluate the suppressive effects of MDSCs on T-cell proliferation (Long et al., 2016; PMID: 27549124). 1A7 was used for detecting the GD2 CAR in flow cytometry analysis (Labanieh et al., 2022; PMID: 35483375). 1A7 was used to sort cells expressing the GD2-specific CARs in FACS (Lamarche et al., 2023; PMID: 36972454).
Antibody first published in:
Sen et al. Preclinical evaluation in nonhuman primates of murine monoclonal anti-idiotype antibody that mimics the disialoganglioside GD2 Clin Cancer Res. 1997 Nov;3(11):1969-76. PMID:9815586
Note on publication:
Describes the generation, characterization and preclinical trials of the anti-idiotypic antibody 1A7.